Other functions: preclinical in vitro and in vivo agent development assays
Ended Awarded Last action
- Contract number
- HHSN261201200018I
- Awardee
-
Weill Medical College Of Cornell University UEI YNT8TCJH8FQ8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 6 $2,395,802 obligated
Award facts
- Combined order value
- $2,395,802 Current and potential, with all options
- Last date to order 100% complete
- Maximum order
- $5,000,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a multiple-award indefinite delivery/indefinite quantity (IDIQ) contract to Weill Medical College of Cornell University to provide preclinical research services for the PREVENT Cancer Preclinical Drug Development Program. Under this $149,995,000 IDIQ, the contractor performs efficacy testing, biomarker evaluation, and analytical assay development to advance cancer preventive agents for clinical trials. The contract has three separate pools: the PREVENT Efficacy Pool, PREVENT CGMP Pool, and PREVENT Toxicology and Pharmacology Pool. Through task orders, NCI seeks support across these areas to establish a structured approach for transitioning cancer preventive drugs and vaccines from discovery to the clinic. Sample task orders include studies on the effect of a chemopreventive agent on the fecal metabolite profile in intestinal neoplasia, development of a polyvalent vaccine against fusion proteins observed in solid tumors, repurposing itraconazole for topical treatment of basal cell carcinoma, and evaluating blood-based biomarkers of obesity-induced breast inflammation. Weill Medical College, a private non-profit research university, performs this work at its facilities in New York.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract HHSN261201200018I?
HHSN261201200018I was awarded to Weill Medical College Of Cornell University by National Cancer Institute (National Institutes of Health) on September 20, 2012.
How much is contract HHSN261201200018I worth?
Orders under HHSN261201200018I have obligated $2,395,802. A single order can be worth up to $5,000,000.
How many orders have been placed under contract HHSN261201200018I?
6 orders have been placed under HHSN261201200018I, the latest on February 26, 2015.
Who can order from contract HHSN261201200018I?
HHSN261201200018I is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract HHSN261201200018I part of a contract vehicle?
Yes. HHSN261201200018I is part of Preclinical Agent Development Assays 2012-2016.
Was contract HHSN261201200018I competed?
The extent of competition for HHSN261201200018I was full and open competition. The government received 5 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV